Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, PR China; Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Changsha 410013, PR China.
Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, PR China; Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Changsha 410013, PR China; Department of Radiology, The Second Xiangya Hospital, Central South University, Changsha 410078, China.
Biotechnol Adv. 2023 Nov;68:108244. doi: 10.1016/j.biotechadv.2023.108244. Epub 2023 Aug 29.
Beta-galactosidase (β-gal), a typical glycosidase catalyzing the hydrolysis of glycosidic bonds, is regarded as a vital biomarker for cell senescence and cancer occurrence. Given the advantages of high spatiotemporal resolution, high sensitivity, non-invasiveness, and being free of ionizing radiations, fluorescent imaging technology provides an excellent choice for in vivo imaging of β-gal. In this review, we detail the representative biotech advances of fluorescence imaging probes for β-gal bearing diverse fidelity-oriented improvements to elucidate their future potential in preclinical research and clinical application. Next, we propose the comprehensive design strategies of imaging probes for β-gal with respect of high fidelity. Considering the systematic implementation approaches, a range of high-fidelity imaging-guided theragnostic are adopted for the individual β-gal-associated biological scenarios. Finally, current challenges and future trends are proposed to promote the next development of imaging agents for individual and specific application scenarios.
β-半乳糖苷酶（β-gal）是一种典型的糖苷酶，能够催化糖苷键的水解，被认为是细胞衰老和癌症发生的重要生物标志物。由于荧光成像技术具有时空分辨率高、灵敏度高、非侵入性和无电离辐射等优点，因此是体内β-gal 成像的绝佳选择。在本文中，我们详细介绍了具有不同保真度改进的代表性荧光成像探针的生物技术进展，以阐明它们在临床前研究和临床应用中的未来潜力。接下来，我们针对高保真度提出了β-gal 成像探针的综合设计策略。考虑到系统的实施方法，针对个体β-gal 相关的生物学情况，采用了一系列高保真度的成像引导治疗方法。最后，提出了当前的挑战和未来的趋势，以促进针对个体和特定应用场景的成像剂的进一步发展。
